The
blood testing market size was valued at USD 89.5 billion in 2022 and is
projected to grow from USD 96.57 Billion in 2023 to USD 152.39 billion by 2030,
exhibiting a compound annual growth rate (CAGR) of 7.90% during the forecast
period (2023 - 2030).
The
blood testing market continues its upward trajectory, fueled by
increasing healthcare awareness and technological advancements. With rising
chronic diseases like diabetes, cardiovascular ailments, and infectious
diseases, demand for blood tests is soaring. Molecular diagnostics,
point-of-care testing, and immunoassays are key segments experiencing notable
growth. Furthermore, COVID-19 pandemic accentuated the importance of blood
testing for diagnosis, surveillance, and antibody detection. Companies are
innovating to enhance accuracy, speed, and convenience, while regulatory bodies
are streamlining approval processes. The market witnesses fierce competition
with major players expanding their portfolios through acquisitions and
partnerships. As healthcare systems emphasize preventive care, the blood
testing market is poised for sustained expansion.
The
blood testing market is witnessing a significant surge in demand, driven by the
growing awareness of preventive healthcare and the increasing prevalence of
chronic diseases. Among the array of blood tests, CBC (Complete Blood Count)
blood tests and hematocrit measurements stand out as vital diagnostic tools.
CBC blood tests provide comprehensive insights into
various blood components, including red blood cells, white blood cells, and
platelets. Healthcare professionals rely on CBC tests to assess overall health
status, detect infections, monitor existing conditions like anemia or leukemia,
and evaluate response to treatments.
Hematocrit,
a key component measured in CBC tests, refers to the proportion of red blood
cells in the blood. It plays a crucial role in oxygen transport throughout the
body. Abnormal hematocrit levels can indicate conditions such as dehydration,
anemia, or polycythemia.
The
demand for CBC blood tests and hematocrit
measurements is poised to grow further with the rising incidence of blood
disorders and the emphasis on early disease detection. As healthcare providers
increasingly prioritize preventive care, the blood testing market is expected
to expand globally.
Moreover,
technological advancements, such as automated analyzers and point-of-care
testing devices, are enhancing the efficiency and accuracy of blood testing
procedures. This trend is likely to fuel market growth and improve
accessibility to essential diagnostic services, ultimately contributing to
better patient outcomes and healthcare management.
Global
Blood Testing Market – Segments
The
report is segmented into five dynamics;
By
Test Type: Direct LDL Testing, Glucose Testing, Lipid Panel Testing, Prostate
Specific Antigen (PSA) Testing, A1C Testing, Blood Urea Nitrogen (BUN) Testing,
High Sensitivity C-Reactive Protein (hs-CRP) Testing, Alt Testing, Vitamin D
Testing, Thyroid Stimulating Hormone Testing, Serum Nicotine/Cotinine Testing,
Creatinine Testing, AST Testing, Testosterone Testing, Cortisol Testing, and
others.
By
Disease : Infection, Anemia,
Leukemia, Kidney Disorders, Hypokalemia, Coronary Heart Disease, Heart Attack,
and other diseases.
By
Method : Automated Blood Culture
Testing, Manual Blood Culture Testing, and others.
By
End-User : Hospitals, Clinics,
Diagnostic Centers, Research Labs, and others.
By
Regions : Europe, Americas, Asia Pacific, and the
Rest-of-the-World (RoW).
Global
Blood Testing Market – Regional Analysis
North
America dominates the global blood testing market. Market growth attributes to
the rising prevalence of kidney disorders, bloodstream infections, other
infections, and demand for rapid diagnostic tests. Besides, factors such as
early adoption of advanced medical technologies and continuous development by
industry players impact the market growth positively.
Moreover,
the presence of large numbers of industry players and well-developed healthcare
sectors in the region boost market growth. The North American blood testing
market is projected to retain its dominance over the global market throughout
the assessment period.
Europe
stands second in the global blood testing market. The market is propelled by
the rise in research expenses and technological advances. Also, the increasing
awareness for chronic infection diseases and initiatives undertaken by public
and private sectors boost the market growth. Moreover, factors such as
accelerating health concerns and demand for innovative and effective therapies
boost the regional market growth.
Also,
the growing prevalence of various chronic diseases and hematological disorders
push regional market growth. Furthermore, the presence of prominent market
players in the region impacts market growth positively. The European blood
testing market is estimated to create a substantial revenue pocket during the
forecast period.
The
Asia Pacific blood testing market is growing rapidly. Factors such as the
increasing awareness of the importance of diagnostics in personalized medicines
and government initiatives to promote the use of personalized medicines drive
market growth. Furthermore, the increase in the number of government schemes to
curb the skyrocketing healthcare expenditures influence market growth.
Moreover,
the rising adoption rate of blood testing tests and increasing healthcare
expenditure of demographics foster the growth of the market. China and India
are hotspots for investment opportunities due to the growing numbers of
diagnoses, treatments, research activities, healthcare modernization, and
quality improvisations.
Major
Players:
The global blood testing market players Include
are Baxter International (U.S.), Abbott Laboratories Inc. (U.S.), Gen-Probe,
Inc. (U.S.), Becton Dickinson & Company (U.S.), Novartis Diagnostics
(U.S.), Biomerica, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Cepheid
Corporation (U.S.), Trinity Biotech (U.S.), Siemens Healthcare (Germany),
Bio-Rad Laboratories Inc. (U.S.), Grifols (Spain), bioMérieux (France),
Nanosphere Inc. (U.S.), Roche Diagnostics (Switzerland), Bruker Corporation
(U.S.), Alere Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.) Cardinal Health
(U.S.), Beckman Coulter (U.S.), Danaher Corporation (U.S.), and Trividia Health
(U.S.), among others.
Related
Reports:
Medical Digital Imaging Devices
Anticholinergic Drugs
Dental Forceps
Blockchain in Pharmaceutical
Supply Chain Management
Inhalation Anesthesia
For More
Information, Please Visit @ Market
Research Future
Comments
Post a Comment